Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | B-PRISM: Phase II trial of Dara-VRd in high-risk smoldering multiple myeloma

Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, summarizes the positive results of the B-PRISM study (NCT04775550), which is evaluating the safety and efficacy of daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) in patients with high-risk smoldering multiple myeloma (HR-SMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Advisory boards: Janssen, BMS, Takeda, Sanofi, GPCR Therapeutics, GSK